Please login to the form below

Not currently logged in
Email:
Password:

UCB forms alliance with Harvard

UCB is to collaborate with Harvard University on the research of therapies for conditions related to the central nervous system and immunology

UCB is to collaborate with Harvard University on the research of therapies for conditions related to the central nervous system and immunology.

The Belgium-based biopharma company will provide Harvard scientists with up to $6m over two years to fund innovative research projects in the specialist areas.

Expertise in antibody generation and medicinal chemistry will also be provided by UCB.

The company said it aims to 'capitalise' on external scientific research, with the collaboration intended as a 'two-way exchange of knowledge and expertise' to help develop new drugs, according to Ismail Kola, president of UCB NewMedicines.

The first project to receive funding from the collaboration is a study looking at developing antibodies against a specific target with implications for diabetes and metabolic disorders. It is led by Professor Gökhan S Hotamisligil, Department of Genetics and Complex Diseases, Harvard School of Public Health.

Regular meetings will be held between the university and UCB to decide what future projects to fund.

Isaac T Kohlberg, chief technology development officer at Harvard, was positive about the potential benefits for the university from the collaboration: "It exemplifies Harvard's growing commitment to collaborate with industry in creative ways that will advance the boundaries of translational research, thereby realising our core mission to serve the public interest."

The announcement follows a collaboration between sanofi-aventis and Harvard focusing on translational biomedical research in therapeutic areas, including cancer and diabetes.

28th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....

Infographics